跳至主要内容
临床试验/EUCTR2013-003405-26-ES
EUCTR2013-003405-26-ES进行中(未招募)1 期

The effect of Lamotrigine on cognitive deficits associated with Neurofibromatosis type 1: a phase II randomized controlled multi-centre trial (NF1-EXCEL)

Erasmus MC0 个研究点目标入组 60 人开始时间: 2017年7月31日最近更新:
相关药物

试验速览

阶段
1 期
状态
进行中(未招募)
发起方
Erasmus MC
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • NF1 patients with a genetically confirmed diagnosis
  • Age 12-17.5 years at inclusion
  • Oral and written informed consent by parents and assent from participants
  • Are the trial subjects under 18? yes
  • Number of subjects for this age range: 60
  • F.1.2 Adults (18-64 years) no
  • F.1.2.1 Number of subjects for this age range
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • -Segmental NF1
  • -Hearing problems or deafness
  • -Use of the following medication: fenytoïn, carbamazepine, fenobarbital, primidon, rifampicine, atazanavir/ritonavir, lopinavir/ritonavir, oxcarbazepine, topiramate, oral contraceptive pill (oestrogen and progestagen) and valproic acid during the last 3 months.
  • -Previous use of lamotrigine
  • -Previous allergic reactions to anti-epileptic drugs
  • -Epilepsy or epilepsy in the past
  • -Suicidal thoughts or behaviour
  • -Renal insufficiency
  • -Liver insufficiency
  • -Pregnancy
  • -Brain tumour or other brain pathology potentially influencing the outcome measures

研究者

发起方
Erasmus MC

相似试验